Rotting at the dockRoivant Sciences $ROIV
Saw revenue fall 71.6% in FY2026 to $8 million, operating margin -6236% against a -3.8% median for pharmaceutical preparations, equity 79.3% of assets.
Last filing8-K · Item 7.01 Regulation FD Disclosure, 21 Oct 2026
Edgarette’s full reading · exposure, experience, soundness, credibility, range
🫧 Edgar looked up ROIVANT SCIENCES LTD. ($ROIV). Last filing: 8-K (7.01 Regulation FD Disclosure), 2026-10-21. 13 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $8.3M (FY2026). Experience: revenue down 71.6% on the year, down 37.8% a year over 4 years; operating margin -6235.7%, down from -3453.3%. Soundness: equity 79.3% of assets, return on equity -8.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.1M and $12.6M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $961K to $15.0M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -6235.7% against a -3.8% median; growth -71.6% against 13.7%.
Read from its own SEC filings · nothing written, nothing inferred
Speed and cash · fiscal 2025
Both views must agree for a label · a description, not advice.
| Cash flow (op · inv · fin · free) | −$750M · −$682M · $134M · −$759M |
| Investment book (cash · short · long) | $1.4B · $2.1B · $727M · current ratio 18.37 · unrealized −$4M |
| Revenue swing · equity of assets | 77.5% · 81.7% |
Roivant Sciences is growing slower than its size class, with revenue that swings more. Its own audited SEC figures.
The figures, as filed
| Fiscal year end | 2026-03-31 |
| Revenue | $8M |
| Revenue, on the year | −71.6% |
| Revenue, a year over the record | −37.8% |
| Operating margin | −6235.7% |
| Operating margin, prior year | −3453.3% |
| Net margin | −4817.3% |
| Research and development | $682M · 8254.4% of revenue |
| Total debt | — |
| Equity of assets | 79.3% |
| Return on equity | −8.8% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-0.54 |
| Book value per share | $6.52 |
| Revenue per share | $0.01 |
| Shares outstanding | 693,864,530 |
| Audited years read | 5 |
Peers: the median of 114 filers with $50M+ revenue in pharmaceutical preparations.
Classic signals · fiscal 2026Altman Z″ 16.14 safe zone 1968Piotroski F 2 of 9 weak 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals 6.3% modest accruals 1996DuPont ROE -8.6% = margin -4817.3% × turns 0 × leverage 1.21
What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →
Health HarborRoivant Sciences sails as: Rotting at the dock
Health watch · 12 monthsquiet · none of the watched events filed
Tied up at the dock.
🌊 Visit the Bay →- slow and jumpy: growing slower than its size class, with revenue that swings more
- operating cash flow was negative
- operating loss: a margin of -6235.7% in FY2026
- revenue is hard to predict: its 80% range is ±84%
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
- 8-K · 2026-10-21 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 8-K · 2026-09-18 · 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits
- 8-K · 2026-09-08 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 8-K · 2026-08-28 · 8.01 Other Events; 9.01 Financial Statements and Exhibits
- 8-K · 2026-08-27 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 10-Q · 2026-08-06
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company